Retractable Technologies, Inc. (RVP) AI Stock Analysis

Retractable Technologies, Inc. specializes in the design, development, manufacturing, and global distribution of safety syringes and other medical safety products for healthcare providers. Headquartered in Little Elm, Texas, the company supplies markets across the United States, North and South America, and internationally. Its product portfolio includes VanishPoint insulin syringes, tuberculin syringes, allergy antigen syringes, Patient Safe syringes, Luer Caps, VanishPoint autodisable syringes, and EasyPoint needles. It also produces safety medical devices like small diameter tube adapters, blood collection tube holders, and IV safety catheters, distributed through direct marketing and global distributor networks.

From FY2021 to FY2025, revenue contracted at a 5-year CAGR of -14.1%, falling from $188.4M in FY2021 to $38.3M in FY2025. Gross margin shrank from 50.6% in FY2021 to 0.1% in FY2025, while operating margin deteriorated from 38.5% to -52.8%. The company posted net income of $56.1M in FY2021 but recorded a net loss of -$12.6M in FY2025, alongside negative free cash flow of -$7.6M. For the latest quarter ended June 30, 2026, quarterly revenue fell 31.1% year-over-year, quarterly earnings fell 66.7%, and trailing twelve month revenue reached $33.9M with an operating margin of -71.5%.

As of June 30, 2026, Retractable Technologies held $39.9M in cash and short-term investments against total debt of $715,921, producing net cash of $39.2M. The company has a current ratio of 4.93 and a debt-to-equity ratio of 0.01 with shareholders' equity of $72.9M across total assets of $141.7M. In FY2025, operating cash flow stood at -$7.1M, while capital expenditures were $535,644 and dividends paid totaled $230,444. Over 5 years, the share count declined 12.6%.

At a share price of $0.58, Retractable Technologies has a market cap of $17.2M and an enterprise value of -$18.0M due to its net cash holdings. Its price-to-sales multiple is 0.5x, compared to 4.1x for the median of its US-listed Healthcare peers, and its EV-to-EBITDA stands at 0.5x versus the peer median of 12.0x. Over the past year, RVP fell 40.8% while the S&P 500 (SPY) gained 16.8%. Over five years, the stock dropped 93.7% against an 83.0% gain for the benchmark index.

Wall Street analyst ratings, consensus price targets, and forward earnings estimates are not published for Retractable Technologies. The company does not have tracked earnings surprises or consensus revision data in the available figures. The next scheduled quarterly earnings report date is November 13, 2026. Without formal analyst forecasts, performance tracking relies on historical results, such as the trailing twelve month EPS of -$0.12 and annual EPS of -$0.19 reported for FY2025.

This page is an AI-written research summary of Retractable Technologies, Inc. (RVP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RVP income statement, RVP balance sheet, RVP key metrics, RVP chart. See the RVP stock overview for the latest quote and news.